AI summary by TwinMind
How can we solve the antibiotic resistance crisis? - Gerry Wright
TED-Ed
6m 22s
Historical Development of Antibiotics
- Penicillin discovered 1928 by Alexander Fleming
- Fleming's 1945 Nobel Prize speech warned of bacterial resistance potential
- 1940s-50s: resistant bacteria began appearing
- 1940s-1980s: pharmaceutical companies countered resistance by discovering many new antibiotics
- Initially highly successful and profitable enterprise
- Mid-1980s: no new chemical classes of antibiotics discovered since then
Decline in Antibiotic Profitability
- Newly discovered antibiotics effective only for narrow spectrum infections
- Versus early antibiotics with broad applicability
- Fewer doses sold = less profitable
- Early days: heavy overprescription including viral infections
- Increased prescription scrutiny reduced sales (positive but impacted profits)
- Companies shifted to lifetime medications development
- Blood pressure, cholesterol medications
- Anti-depressants, anti-anxiety medications
- More profitable due to indefinite usage
Current Resistance Problem
- Bacteria acquire resistance through genetic information sharing
- Between individual bacteria
- Across species
- Multi-antibiotic resistant bacteria now common
- Some strains resistant to all current drugs
Solutions Framework
- Control existing antibiotic use
- Create new antibiotics
- Combat resistance to new/existing drugs
- Find new ways to fight bacterial infections
Agricultural Antibiotic Use
- Agriculture = largest antibiotic consumer
- Uses: treat infections + promote food animal growth
- Large volumes increase bacterial exposure and resistance development
- Common bacteria (salmonella) infect both animals and humans
- Drug-resistant versions pass through food chain
- Spread via international trade and travel networks
New Antibiotic Discovery Approaches
- Nature offers most promising compounds
- Organisms (microbes, fungi) evolved in competitive environments
- Contain antibiotic compounds for survival advantage
- Package antibiotics with resistance-inhibiting molecules
- Target bacterial proteins that degrade drugs
- Phages (viruses attacking bacteria, not humans)
- Vaccines for common infections prevent disease
Funding Crisis
- Inadequate funding globally
- Large pharmaceutical companies stopped antibiotic development
- Small companies bringing new antibiotics to market go bankrupt
- Example: American startup Achaogen
- Fundamental profitability problem
- Effective treatments used once = difficult to profit
- Successful resistance counteraction requires sparing use = lower profits
Potential Solutions
- Shift profits away from antibiotic volume sold
- UK testing antibiotic subscription model for healthcare providers
- Government incentive programs in early stages
- Need much more global investment
- Controlled use of current drugs combined with development investment can overcome resistance
